Total Payments
$241,122
2024 Payments
$48,234
Companies
11
Transactions
168
Medicare Patients
7,844
Medicare Billing
$382,813
Payment Breakdown by Category
Other$175,254 (72.7%)
Consulting$47,817 (19.8%)
Travel$12,423 (5.2%)
Food & Beverage$3,992 (1.7%)
Research$1,560 (0.6%)
Education$75.24 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $164,454 | 63 | 68.2% |
| Consulting Fee | $47,817 | 12 | 19.8% |
| Travel and Lodging | $12,423 | 32 | 5.2% |
| Honoraria | $10,800 | 1 | 4.5% |
| Food and Beverage | $3,992 | 56 | 1.7% |
| Unspecified | $1,560 | 2 | 0.6% |
| Education | $75.24 | 2 | 0.0% |
Payments by Type
General
$239,562
166 transactions
Research
$1,560
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $152,261 | 82 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $51,403 | 39 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $17,848 | 13 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $17,807 | 13 | $0 (2024) |
| Abbott Laboratories | $1,100 | 15 | $0 (2023) |
| Impulse Dynamics (USA) Inc. | $187.58 | 1 | $0 (2021) |
| ABIOMED | $148.30 | 1 | $0 (2022) |
| Boston Scientific Corporation | $137.20 | 1 | $0 (2022) |
| CARDIVA MEDICAL, INC. | $100.08 | 1 | $0 (2017) |
| Akcea Therapeutics, Inc. | $79.67 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,234 | 31 | PFIZER INC. ($22,333) |
| 2023 | $40,780 | 40 | PFIZER INC. ($39,736) |
| 2022 | $37,057 | 26 | PFIZER INC. ($19,724) |
| 2021 | $38,977 | 19 | PFIZER INC. ($30,300) |
| 2020 | $36,845 | 19 | PFIZER INC. ($29,368) |
| 2019 | $30,775 | 25 | PFIZER INC. ($10,800) |
| 2018 | $8,262 | 6 | Novartis Pharmaceuticals Corporation ($8,262) |
| 2017 | $192.49 | 2 | CARDIVA MEDICAL, INC. ($100.08) |
All Payment Transactions
168 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,250.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $100.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/25/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $110.17 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $100.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/06/2024 | PFIZER INC. | VYNDAMAX (Drug) | Food and Beverage | In-kind items and services | $78.48 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/04/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $78.24 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/26/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/16/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,400.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/12/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/12/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,759.00 | General |
| 05/29/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/29/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Travel and Lodging | In-kind items and services | $1,268.75 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/29/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Travel and Lodging | In-kind items and services | $550.74 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/29/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $37.36 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/14/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $4,165.00 | General |
| 05/14/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | Cash or cash equivalent | $319.46 | General |
| 05/14/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | Cash or cash equivalent | $118.00 | General |
| 05/14/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | Cash or cash equivalent | $58.00 | General |
| 05/03/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,400.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/01/2024 | PFIZER INC. | VYNDAQEL (Drug) | Travel and Lodging | In-kind items and services | $861.05 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $94.06 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $55.00 | General |
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 04/05/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $35.68 | General |
| 03/20/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,410.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,560 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,955 | 2,092 | $303,630 | $85,121 |
| 2022 | 19 | 2,073 | 2,289 | $337,903 | $98,931 |
| 2021 | 18 | 1,945 | 2,149 | $307,902 | $94,449 |
| 2020 | 18 | 1,871 | 2,221 | $316,898 | $104,313 |
Total Patients
7,844
Total Services
8,751
Medicare Billing
$382,813
Procedure Codes
78
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Facility | 2023 | 280 | 280 | $69,440 | $17,942 | 25.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 57 | 146 | $31,850 | $13,482 | 42.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 66 | 68 | $34,612 | $9,044 | 26.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 54 | 62 | $17,918 | $8,167 | 45.6% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Facility | 2023 | 273 | 273 | $44,772 | $5,917 | 13.2% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 329 | 329 | $19,411 | $5,160 | 26.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 50 | 54 | $11,178 | $4,724 | 42.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 35 | 42 | $12,138 | $4,449 | 36.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 30 | 30 | $12,750 | $4,426 | 34.7% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 345 | 345 | $13,110 | $3,599 | 27.5% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 36 | 36 | $11,016 | $1,974 | 17.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 251 | 269 | $5,918 | $1,607 | 27.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 14 | 14 | $3,766 | $1,186 | 31.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 23 | $4,991 | $1,174 | 23.5% |
| 78451 | Nuclear medicine study of heart muscle at rest and with stress and spect | Facility | 2023 | 20 | 20 | $5,100 | $973.25 | 19.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 68 | 73 | $3,650 | $757.42 | 20.8% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 15 | 15 | $1,035 | $295.94 | 28.6% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 13 | 13 | $975.00 | $241.56 | 24.8% |
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Facility | 2022 | 284 | 284 | $70,432 | $18,718 | 26.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 71 | 183 | $37,515 | $14,626 | 39.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 100 | 116 | $24,012 | $10,505 | 43.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 49 | 49 | $24,941 | $7,575 | 30.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 50 | 57 | $16,473 | $7,563 | 45.9% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Facility | 2022 | 263 | 263 | $43,132 | $5,901 | 13.7% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2022 | 348 | 349 | $20,591 | $5,696 | 27.7% |
About Dr. Brett Sperry, MD
Dr. Brett Sperry, MD is a Internal Medicine healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/07/2010. The National Provider Identifier (NPI) number assigned to this provider is 1982920534.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brett Sperry, MD has received a total of $241,122 in payments from pharmaceutical and medical device companies, with $48,234 received in 2024. These payments were reported across 168 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($164,454).
As a Medicare-enrolled provider, Sperry has provided services to 7,844 Medicare beneficiaries, totaling 8,751 services with total Medicare billing of $382,813. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Cardiovascular Disease, Advanced Heart Failure and Transplant Cardiology
- Location Kansas City, MO
- Active Since 04/07/2010
- Last Updated 07/06/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1982920534
Products in Payments
- VYNDAQEL (Drug) $152,182
- ONPATTRO (Drug) $31,760
- ENTRESTO (Drug) $17,754
- WAINUA (Drug) $8,134
- AMVUTTRA (Drug) $7,500
- CardioMEMS HF System (Device) $357.78
- Optimizer Smart System (Device) $187.58
- CARDIOMEMS (Device) $160.88
- COROFLOW (Device) $153.52
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $150.00
- Impella (Device) $148.30
- AVVIGO Guidance System (Device) $137.20
- Confirm Rx (Device) $104.94
- Vascular Closure Device (Device) $100.08
- LEQVIO (Drug) $94.06
- Circulatory Support (Device) $92.41
- TEGSEDI (Drug) $79.67
- VYNDAMAX (Drug) $78.48
- HeartMate Touch (Device) $48.86
- HeartMate 3 Left Ventricular Dev (Device) $31.55
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Kansas City
James O'keefe, Md, MD
Internal Medicine — Payments: $834,178
Internal Medicine $834,178
Shadi Hamdeh, Md, MD
Internal Medicine — Payments: $623,244
Internal Medicine $623,244
Dr. Patrick Moriarty, M.d, M.D
Internal Medicine — Payments: $618,967
Internal Medicine $618,967
Gerald Mancuso, M.d, M.D
Internal Medicine — Payments: $615,894
Internal Medicine $615,894
Dr. Ryan Taylor, M.d, M.D
Internal Medicine — Payments: $512,094
Internal Medicine $512,094
Sanjaya Gupta, Md, MD
Internal Medicine — Payments: $325,155
Internal Medicine $325,155